LYSALGO ® Mefenamic acid

LYSALGO ® is a drug based on mefenamic acid

THERAPEUTIC GROUP: Non-steroidal anti-inflammatory and antirheumatic drugs

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications LYSALGO ® Mefenamic acid

LYSALGO ® is indicated in the treatment of painful states on an inflammatory basis, both acute and chronic, of mild and modest entity.

Mechanism of action LYSALGO ® Mefenamic acid

The mefenamic acid, active ingredient of LYSALGO ®, is a molecule belonging to the family of non-steroidal anti-inflammatory drugs, and more specifically to that of aromatic acids, representing the forefather of the chemical class of phenamic acid derivatives.

Taken orally it is rapidly absorbed at the level of the terminal part of the small intestine, reaching maximum plasma concentration in about 60 minutes.

Largely linked to plasma proteins, after a first-pass metabolism, it is distributed among the various tissues, where, like other non-steroidal anti-inflammatory drugs, it binds cyclooxygenases by exercising a competitive antagonist action.

The inhibition of these enzymes, normally involved in the conversion of arachidonic acid into prostaglandins, results in a reduction in the synthesis of chemical mediators with vasopermealising, vasodilatory, chemotactic, algogenic action, usually involved in the genesis of pain and inflammation.

After its activity, considering an average half-life of about 2 hours, after intense hepatic metabolism it is mainly excreted via the kidneys.

Studies carried out and clinical efficacy

1. THE MEFENAMIC ACID IN THE PROTECTION FROM NEURONAL DAMAGE

Free Radic Res. 2012 Mar 16.

Recent study that shows how the use of non-steroidal anti-inflammatory drugs such as mefenamic acid can be effective in protecting nerve cells from neurotoxic damage induced by different chemical agents.

2 .AANAPHYLASSES TO MEHENAMIC ACID

Allergol Immunopathol (Madr). 2010 Jul-Aug; 38 (4): 224-6. Epub 2010 Feb 12.

Interesting case report that demonstrates the onset of a serious adverse reaction to mefenamic acid, further complicated by a picture of anaphylaxis, in a patient suffering from systemic lupus erythematosus.

3. THE EFFECTIVENESS OF MEFENAMIC ACID IN PRIMARY SORRY

J Altern Complement Med. 2009 Feb; 15 (2): 129-32.

Work that shows how mefenamic acid can be effective in reducing pain associated with dysmenorrhea, without inducing clinically relevant side effects.

Method of use and dosage

LYSALGO ®

Capsules containing 250 mg of mefenamic acid:

the posologic scheme useful in the treatment of painful states on a phlogistic basis involves taking 2 capsules 3 times a day in the attack phase and 1 capsule 3 times a day in the subsequent maintenance phase.

In order to reduce the potential side effects associated with NSAID therapy, it would be recommended to take LYSALGO ® preferably on a full stomach and for limited periods of time.

All treatment should be supervised by your doctor.

Warnings LYSALGO ® Mefenamic acid

Treatment with drugs such as mefenamic acid should be understood as a short-term symptomatic therapy.

In order to minimize the incidence of side effects combined with therapy, it would be appropriate to start treatment with the minimum effective dose, taking care to take the drug preferably on a full stomach and adjust the doses in case of elderly patients or patients suffering from liver diseases. kidney.

Particular caution should also be reserved for patients suffering from cardiovascular, coagulative, renal, hepatic, allergic and gastrointestinal pathologies, given the greater susceptibility of these to the side effects of NSAID therapy.

If undesired effects appear, the patient, after contacting his doctor, should seriously consider suspending therapy.

PREGNANCY AND BREASTFEEDING

The use of LYSALGO ® is contraindicated in pregnancy, given the numerous studies in the literature that show the toxic effects of non-steroidal anti-inflammatory drugs on correct fetal development.

Cardiovascular and respiratory malformations and unwanted abortions are the risks most frequently associated with NSAID-based therapy.

Interactions

Mefenamic acid, as well as the other active ingredients belonging to the category of non-steroidal anti-inflammatory drugs, is particularly susceptible to pharmacological interactions, capable of appreciably varying its therapeutic properties and the related safety profile.

For this reason, particular attention should be paid to the concomitant administration of

Oral anticoagulants and inhibitors of serotonin reuptake, due to the increased risk of bleeding;
Diuretics, ACE inhibitors, angiotensin II antagonists, methotrexate and ciclosporin, for cpacity enhance the hepatotoxic and nephrotoxic effects of acetylsalicylic acid;
Non-steroidal anti-inflammatory and corticosteroids, for damage to the gastro-intesintal mucosa
Antibiotics, due to the variations induced in terms of pharmacokinetic and pharmacodynamic properties;
Sulfonylureas, for alterations affecting glucose metabolism, potentially responsible for sudden and severe hypoglycemia.

Contraindications LYSALGO ® Mefenamic acid

Intake of LYSALGO ® is contraindicated in case of hypersensitivity to the active substance or to one of its excipients, angioedema, peptic ulcer, history of intestinal bleeding, ulcerative colitis, Crohn's disease or previous history for the same diseases, cerebrovascular bleeding, haemorrhagic diathesis or concomitant anticoagulant therapy, renal failure, liver failure, asthma, hypophosphataemia and viral infections.

Undesirable effects - Side effects

LYSALGO ® therapy exposes the patient to the same side effects commonly described for the various treatments based on non-steroidal anti-inflammatory drugs.

Among the most frequently observed adverse reactions are those related to:

Gastrointestinal system with gastric pyrosis, gastralgia, nausea and vomiting, constipation and in more severe cases ulcers and hemorrhages;
Hematopoietic system with increased bleeding time accompanied in severe cases by pan cytopenia;
Nervous and sensory system with loss of hearing and sight, headache, insomnia, drowsiness, confusion and tremors;
Integumentary system with erythema, rash, urticaria and in severe cases bullous reactions.

Particularly interesting are also the results of different studies, in which long-term treatment with NSAIDs has been associated with a significant increase in cerebro and cardiovascular pathological events.